Talaris Therapeutics, Inc.

CG Oncology, Inc. achieved what no biopharmaceutical company has been able to do for more than two months – it went public in the US. The bladder cancer drug developer also launched the first initial

PTC Therapeutics, Inc. will receive $1bn as it expands a deal it did with Royalty Pharma plc in 2020 around royalties from the PTC/ Roche Holding AG -partnered spinal muscular atrophy drug Evrysdi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Leo To Pay $14m For Timber, Plus Milest

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge